Incysus Therapeutics, Inc.

3:00 PM - 3:15 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. The company has received FDA approval for two INDs and expects to initiate two Phase I programs in 2019.
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ICY-200
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided